skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pegylated liposomal doxorubicin in ovarian cancer

(2728) Views  (513) Full article downloads

Authors: Andrew E Green, Peter G Rose

Published Date May 2006 Volume 2006:1(3) Pages 229 - 239
DOI: http://dx.doi.org/10.2147/IJN.S

Andrew E Green, Peter G Rose

Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH, USA

Abstract: Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions of this formulation, the Phase II and Phase III data that helped define the role of pegylated liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-effects and their management.

Keywords: pegylated lipopsomal doxorubicin, ovarian cancer








Readers of this article also read:

Chitosan nanoparticles for oral drug and gene delivery
Nano-vectors for efficient liver specific gene transfer
Formation of potential titanium antigens based on protein binding to titanium dioxide nanoparticles
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Transport characteristics of nanoparticle-based ferrofluids in a gel model of the brain
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
"Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health
Amino acid-responsive Crohn's disease: a case study
Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease